Back to Investors
Investment Case
A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.
In 2023, the Group generated revenue of €2.6bn, gross profit of €390m and EBITDA of €116m. With a workforce of more than 3,200, the Group is active in Ireland, Europe, USA, APAC and MENA.
Full Year 2023 Results
FY 2023 Key Stats
€116.0m
EBITDA
5.6%
Organic GP Growth YoY
15.2%
ROCE
18.3c
Adjusted EPS
Group Highlights
€390.0m
2023 GP
Employees
Partnering with 7 of the top 10 pharma companies
and 7 of the top 10 medical device companies
